ApprovedFDA approval

Bysanti (milsaperidone)

Vanda Pharmaceuticals (VNDA)

Marketer take

A new antipsychotic from the maker of Fanapt for schizophrenia and bipolar I mania, entering a crowded, mostly generic market where payer step edits and long-acting injectables shape the psychiatry conversation.

Sponsor company
Vanda Pharmaceuticals (VNDA)
Indication
To treat schizophrenia and to treat manic or mixed episodes associated with bipolar I disorder
Therapeutic area
Psychiatry
Event
FDA approval
Date
Feb 20, 2026
Status
Approved
Source
FDA page
Last verified
Nov 15, 2026

Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?

Get alerts when FDA dates move